These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22845481)

  • 1. Hotspot oncomutations: implications for personalized cancer treatment.
    Myers MB; Wang Y; McKim KL; Parsons BL
    Expert Rev Mol Diagn; 2012 Jul; 12(6):603-20. PubMed ID: 22845481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
    Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized targeted therapy in advanced non-small cell lung cancer.
    Ma PC
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutations predict local recurrences in rectal cancer patients.
    He Y; Van't Veer LJ; Mikolajewska-Hanclich I; van Velthuysen ML; Zeestraten EC; Nagtegaal ID; van de Velde CJ; Marijnen CA
    Clin Cancer Res; 2009 Nov; 15(22):6956-62. PubMed ID: 19903786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.
    Didelot A; Le Corre D; Luscan A; Cazes A; Pallier K; Emile JF; Laurent-Puig P; Blons H
    Exp Mol Pathol; 2012 Jun; 92(3):275-80. PubMed ID: 22426079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
    Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
    Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
    Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
    J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncomutations as biomarkers of cancer risk.
    Parsons BL; Myers MB; Meng F; Wang Y; McKinzie PB
    Environ Mol Mutagen; 2010; 51(8-9):836-50. PubMed ID: 20740637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?
    Arnedos M; Soria JC; Andre F; Tursz T
    Cancer Treat Rev; 2014 Dec; 40(10):1192-8. PubMed ID: 25441102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of molecular targeting therapy on tumor immunity].
    Jinushi M; Akita H
    Nihon Rinsho; 2015 Aug; 73(8):1349-54. PubMed ID: 26281689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in older patients with solid tumors.
    Kelly CM; Power DG; Lichtman SM
    J Clin Oncol; 2014 Aug; 32(24):2635-46. PubMed ID: 25071113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches.
    Foster SA; Klijn C; Malek S
    Trends Cancer; 2016 Dec; 2(12):699-701. PubMed ID: 28741516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput mutational analysis of the human cancer genome.
    Ma PC; Zhang X; Wang ZJ
    Pharmacogenomics; 2006 Jun; 7(4):597-612. PubMed ID: 16753007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert M; Hummel M; Bläker H; Müller BM; Lehmann A; Denkert C; Heppner FL; Koch A; Sers C; Anagnostopoulos I
    Cancer Gene Ther; 2013 Apr; 20(4):211-21. PubMed ID: 23492822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine benefits patients in early trials: matching targeted therapies with gene mutations is associated with better outcomes, even in phase 1 studies.
    Printz C
    Cancer; 2012 Oct; 118(20):4911-2. PubMed ID: 23042614
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular pathology as the driving force for personalized oncology.
    Oktay MH; Hui P
    Expert Rev Mol Diagn; 2012 Nov; 12(8):811-3. PubMed ID: 23249199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral heterogeneity and consequences for targeted therapies.
    Turtoi A; Blomme A; Castronovo V
    Bull Cancer; 2015 Jan; 102(1):17-23. PubMed ID: 25609489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying mutation specific cancer pathways using a structurally resolved protein interaction network.
    Engin HB; Hofree M; Carter H
    Pac Symp Biocomput; 2015; 20():84-95. PubMed ID: 25592571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.